Physician
Belilovsky, Anatoly
Belilovsky, Anatoly was paid $7.86M by Medicaid between Jan 2018 and Dec 2024, across 71 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 64% of everything it billed.
33Billing provider infoBELILOVSKY, ANATOLY
BROOKLYN, NY 11235
BROOKLYN, NY 11235
33aNPI1164497913assigned 02/22/2006
33bProvider typePediatrics Physician
28Total paid$7.86M
24GClaims268,623
24DCodes billed71
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in New York
Rank by total paid#33 of 1,983
Median peer was paid$17K
This provider vs. median463×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,568 | $670K | |
| 2019 | 34,210 | $853K | |
| 2020 | 32,355 | $801K | |
| 2021 | 36,392 | $1.18M | |
| 2022 | 49,000 | $1.57M | |
| 2023 | 52,926 | $1.57M | |
| 2024incomplete | 38,172 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 64% | 66,141 | 48,677 | $5.02M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.7% | 4,871 | 4,869 | $450K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.4% | 4,183 | 4,180 | $421K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.3% | 4,454 | 4,385 | $413K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.6% | 4,112 | 3,533 | $360K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.4% | 18,869 | 17,635 | $186K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.2% | 1,640 | 1,634 | $169K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 3,305 | 3,063 | $120K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.5% | 1,142 | 1,142 | $118K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 1.1% | 3,968 | 3,965 | $89K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 33,556 | 30,059 | $80K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,929 | 3,702 | $79K |
59 more codes
| 87428 | <1% | 3,895 | $75K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 16,129 | $48K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 187 | $28K |
| 92570 | <1% | 1,905 | $23K | |
| 96127 | <1% | 4,709 | $22K | |
| 81000 | <1% | 5,932 | $17K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 344 | $17K |
| 99383 | <1% | 153 | $16K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 704 | $15K |
| 90461 | <1% | 4,445 | $12K | |
| 92588 | <1% | 229 | $11K | |
| 93000 | <1% | 809 | $9K | |
| 94664 | <1% | 942 | $8K | |
| 99384 | <1% | 54 | $6K | |
| 90716 | <1% | 1,086 | $6K | |
| 90651 | <1% | 529 | $5K | |
| 96160 | <1% | 1,930 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 39 | $4K |
| 97802 | <1% | 8,071 | $4K | |
| 92587 | <1% | 109 | $3K | |
| 90686 | <1% | 3,262 | $3K | |
| 81025 | <1% | 1,553 | $3K | |
| 90707 | <1% | 475 | $3K | |
| 90715 | <1% | 1,222 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 153 | $1K |
| 99382 | <1% | 12 | $1K | |
| 90710 | <1% | 1,391 | $924.00 | |
| 90744 | <1% | 2,077 | $871.37 | |
| 90473 | <1% | 157 | $783.54 | |
| 90619 | <1% | 1,058 | $730.69 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,451 | $579.76 |
| 90677 | <1% | 451 | $570.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 570 | $458.99 |
| 99173 | <1% | 5,572 | $206.22 | |
| 90633 | <1% | 1,718 | $203.25 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | $194.94 |
| 90674 | <1% | 117 | $141.94 | |
| 90672 | <1% | 968 | $140.92 | |
| 81002 | <1% | 65 | $128.48 | |
| 90734 | <1% | 839 | $110.52 | |
| 82947 | <1% | 38 | $110.20 | |
| 86580 | <1% | 14 | $58.00 | |
| 90713 | <1% | 528 | $45.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 112 | $10.35 |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 12 | $8.91 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $8.27 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 153 | $4.67 |
| 36416 | <1% | 27,306 | $3.24 | |
| 90685 | 0% | 59 | $0.00 | |
| 90700 | 0% | 399 | $0.00 | |
| 90670 | 0% | 1,803 | $0.00 | |
| 90671 | 0% | 120 | $0.00 | |
| 90681 | 0% | 53 | $0.00 | |
| 90647 | 0% | 428 | $0.00 | |
| 90698 | 0% | 1,555 | $0.00 | |
| 90696 | 0% | 632 | $0.00 | |
| 90680 | 0% | 1,539 | $0.00 | |
| 90697 | 0% | 350 | $0.00 | |
| 90723 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.